OptimizeRx Q1 rev $19.8M, adj EBITDA $3.3M; guides FY rev $95-100M, refi saves $1.5M

OptimizeRx Corp

• Q1 revenue $19.8M (down 10% YoY), GAAP net loss $(0.5)M ($(0.03)/share) vs $(2.2)M loss a year ago.
• Non-GAAP net income $2.7M ($0.14/diluted), adjusted EBITDA $3.3M vs $1.5M prior year.
• FY 2026 revenue guidance updated to $95-100M; adjusted EBITDA guidance unchanged $21-25M.
• Refinanced debt with Fifth Third Bank: $25M term loan + $10M revolver, annual interest savings ~$1.5M.
• Launched efficiency initiatives expected to save $3M annually, including $1M in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.